Novo Nordisk's Valuation Trap: Clinical Wins Can't Mask the Price-Cut Arithmetic
Published on 09/09/2026 at 07:20 | Editorial boerse-global.de
There is a peculiar disconnect at the heart of Novo Nordisk's current market narrative. The Danish pharmaceutical group has just delivered what it describes as a world-first in paediatric obesity treatment, yet the share price keeps sliding. The explanation is not hard to find: investors are pricing the company on what is going wrong, not on what is going right.
A Clinical Milestone That Failed to Move the Needle
The Phase III STEP Young trial delivered striking results. Among children aged six to under 12 with obesity, 40.4 percent fell below the obesity BMI threshold after 68 weeks of treatment at full adherence. In the placebo arm, that figure was zero. The study enrolled 165 children, more than 85 percent of whom had severe obesity, and reported no new safety signals.
The data put Novo Nordisk ahead of Eli Lilly in the race to treat younger patients, at least for now. Prescription volumes for GLP-1 drugs among US children under 12 have grown 300-fold since 2019, according to a study in Pediatrics. This is no longer a niche opportunity.
Yet the stock fell 2.1 percent on Tuesday, following a 3.1 percent decline the previous day in New York. The culprit was not the paediatric data. Two Phase III trials of Ziltivekimab in heart failure were halted after an independent data monitoring committee concluded there was a low probability the results would diverge from the earlier failed study. Only one study, in post-heart-attack patients, remains ongoing, with results expected in the first half of 2027.
The Price-Cut Reality Bites
The political headwinds from Washington add a second layer of pressure. From January 2027, Medicare prices for Ozempic, Wegovy and Rybelsus will drop from $959 to $274 per month — a 71 percent reduction, according to the Centers for Medicare & Medicaid Services. A separate pilot programme offers Wegovy for weight loss at just $50 monthly until December 2027.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The secondary article adds another wrinkle: Ozempic and Wegovy are also slated to cost $350 per month through the TrumpRx channel. These concessions secure market access but squeeze margins per unit. The bull case rests on volume growth compensating for lower pricing — a bet that is far from guaranteed.
Meanwhile, new drug classes including orforglipron and retatrutide are advancing, promising either lower costs or greater efficacy. Novo Nordisk is not defending a moat here; it is fighting for share in an increasingly crowded growth market.
Reading the Valuation Signals
On the surface, the equity looks cheap. The price-to-earnings ratio stands at roughly 11, against an industry average of about 22. The five-year historical median was above 35. External valuation models suggest the stock is undervalued by 58 to 66 percent.
But a multiple that has diverged so sharply from its own history reflects more than market inefficiency. It also captures genuine uncertainty about the pipeline and the pricing environment. The share closed at €38.98, some 29 percent below its 52-week high of €54.86, and is down 16 percent over twelve months. The relative strength index of 42.5 points to a stock in neutral-to-weak territory rather than an oversold condition. The shares also sit about 6.2 percent below their 50-day moving average, with annualised volatility of 40 percent signalling persistent nervousness.
The Competitive Calculus
Eli Lilly's Mounjaro has received FDA approval to reduce cardiovascular risk in high-risk type 2 diabetes patients — a development that Reuters notes intensifies competitive pressure on Novo Nordisk's broader GLP-1 expansion. The company's increasing dependence on semaglutide products is a vulnerability that the Ziltivekimab setback only deepens.
The near-term catalysts are now commercial rather than clinical. The oral Wegovy tablet launched in Germany about a week ago, and China has begun its approval review for the oral version. How quickly these products convert into actual sales growth will determine the next directional move. The 52-week low of €30.25 is not far off if competitive dynamics shift further in Lilly's favour.
What Comes Next
The bull narrative rests on the oral tablet winning over patients who prefer pills to injections, on China eventually opening a vast new market, and on the STEP Young data translating into regulatory approvals that unlock a previously untapped patient segment. The bear case is simpler: a shrinking pipeline, intensifying competition and pricing pressure that may not be fully offset by volume gains.
Until the final Ziltivekimab readout in the first half of 2027, the stock will likely be judged on the sales trajectory of the oral Wegovy tablet. The clinical substance is real — the STEP Young results are a genuine advance for paediatric obesity care. But the market is currently rewarding setbacks and punishing progress, and that dynamic shows no sign of reversing soon.
Ad
Novo Nordisk Stock: New Analysis - 9 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
